Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever – Drugs In Development, 2021, provides an overview of the Lassa Fever (Infectious Disease) pipeline landscape.

Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lassa Fever – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Lassa Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lassa Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 4, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Lassa Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Lassa Fever (Infectious Disease).

– The pipeline guide reviews pipeline therapeutics for Lassa Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Lassa Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Lassa Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Lassa Fever (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Lassa Fever (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Lassa Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Curevac NV

Emergent BioSolutions Inc

Etubics Corp

FUJIFILM Toyama Chemical Co Ltd

GeoVax Labs Inc

Globavir Biosciences Inc

Inovio Pharmaceuticals Inc

Kineta Inc

Medigen Inc

RetroVirox Inc

Themis Bioscience GmbH

Zalgen Labs LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Lassa Fever (Lassa Hemorrhagic Fever) - Overview

Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lassa Fever (Lassa Hemorrhagic Fever) - Companies Involved in Therapeutics Development

Curevac NV

Emergent BioSolutions Inc

Etubics Corp

FUJIFILM Toyama Chemical Co Ltd

GeoVax Labs Inc

Globavir Biosciences Inc

Inovio Pharmaceuticals Inc

Kineta Inc

Medigen Inc

RetroVirox Inc

Themis Bioscience GmbH

Zalgen Labs LLC

Lassa Fever (Lassa Hemorrhagic Fever) - Drug Profiles

(Ebola + Lassa Fever + Marburg) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Lassa fever + rabies) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arevirumab-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

favipiravir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GBV-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GEOLM-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hemorrhagic fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-4500 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lassa fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LHF-535 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ML-29 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Lassa Fever - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects

Lassa Fever (Lassa Hemorrhagic Fever) - Product Development Milestones

Featured News & Press Releases

Jul 14, 2021: Batavia successfully uses innovative hip-vax to manufacture IAVI’s lassa fever vaccine candidate for phase I clinical trials

Jun 15, 2021: EDCTP and CEPI Funding moves IAVI's lassa fever vaccine candidate into advanced clinical development

Feb 23, 2021: INOVIO announces first subject dosed in phase 1B clinical trial for its DNA vaccine against lassa fever, INO-4500, in West Africa

Mar 25, 2020: Kineta presents clinical study results of LHF-535 at the International Conference on Antiviral Research (ICAR)

Oct 30, 2019: Themis Bioscience and CEPI trial Lassa fever vaccine

Aug 06, 2019: Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535

Jul 16, 2019: GeoVax announces upcoming presentation of lassa fever vaccine data

Jul 15, 2019: Kineta secures NIAID grant worth up to $5.8M to evaluate LHF-535 in Arenaviruses

May 23, 2019: Inovio doses patients in Phase I trial of Lassa virus vaccine INO-4500

Dec 11, 2018: Batavia Biosciences Partners with IAVI to Advance Development of Vaccine Against Lassa Fever

Sep 26, 2018: GeoVax awarded $2.4 million from U.S. Department of Defense to advance Lassa Fever Vaccine

Sep 15, 2018: Advanced preclinical development and production of master seed virus of GEO-LM01, a novel MVA-VLP vaccine against Lassa Fever

Sep 05, 2018: Kineta initiates first-in-human clinical trial of LHF-535 a novel therapy for lassa fever

Aug 20, 2018: Emergent and Profectus receive CEPI contract for Lassa virus vaccine

Jun 27, 2018: NIAID Scientists Recommend Favipiravir for Human Trials of Lassa Fever Virus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Curevac NV, 2021

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Emergent BioSolutions Inc, 2021

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Etubics Corp, 2021

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by FUJIFILM Toyama Chemical Co Ltd, 2021

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by GeoVax Labs Inc, 2021

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Globavir Biosciences Inc, 2021

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Inovio Pharmaceuticals Inc, 2021

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Kineta Inc, 2021

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Medigen Inc, 2021

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by RetroVirox Inc, 2021

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Themis Bioscience GmbH, 2021

Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline by Zalgen Labs LLC, 2021

Lassa Fever (Lassa Hemorrhagic Fever) – Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports